HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Volume 20, No. 5, May 2016 – Healthcare Systems & Policies in Asia       » Understanding Healthcare Policies in the Philippines: Cancer Care       » Young Innovators under 35       » Healthcare Cost Effectiveness in Singapore       » ASLAN Pharmaceuticals Opens China Office       » A Journey Inside the Human Body       » Treatment Brings New Hope for Patients Suffering From Fatal Lung Disease      
EYE ON CHINA
UroFlex now CE-marked; Chinese SFDA approval for Cellvizio
Mauna Kea Technology's UroFlex confocal miniprobe has received CE mark approval for use during cystoscopy procedures. UroFlex is believed to be the first optical biopsy probe designed for urological applications and allows the company to enter the EUR 1 billion European urology device market. The new probe allows physicians to obtain optical biopsies that may facilitate the diagnosis, surveillance and treatment of patients with bladder cancer. The CE mark extends Mauna Kea's Cellvizio portfolio beyond the gastrointestinal tract and lungs into the field of urology.

Clinical studies have demonstrated that optical biopsies with Cellvizio could help urologists determine if they have removed all cancerous cells during transurethral resection of the bladder tumour, the initial surgical procedure that a patient undergoes after the diagnosis of bladder cancer. Data also showed that optical biopsies can help physicians characterize lesions during long-term surveillance of bladder cancer patients.

In addition, Mauna Kea's Cellvizio has received SFDA approval in China, one of the fastest growing, largest medical device markets in the world. Concurrently, Mauna Kea has entered into a strategic partnership with Fujifilm Investment Co, a subsidiary of Fujifilm Holdings. The partners will work together to develop the Cellvizio market throughout China in various indications, such as gasteroenterology and pulmonology.

Fujifilm benefits from growth in its endoscopy market in China, and has established a strong distribution network all over the country. There are 800 advanced endoscopy centres in tertiary referral hospitals in China, which will constitute the primary target for Cellvizio.

Cellvizio is a probe-based confocal laser endomicroscopy system that provides high-resolution cellular views of tissue inside the body. Cellvizio has 510(k) clearance from the FDA and the European CE mark for use in the gastrointestinal tract, biliary and pancreatic ducts and lungs.

Click here for the complete issue.

NEWS CRUNCH  
news World Immunisation Week 2016
news IoT Asia 2016 Delivers Actionable Solutions for a Sustainable IoT Ecosystem in Asia
news Lite-On presents a new Biomedical Research and Development Centre in Singapore
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  
APBN Editorial Calendar 2016
January:
Guest Editorial - Biotechnology In Korea
February:
Guest Editorial - Biomedical Research Governance
March:
Guest Editorial - Life-Saving Opportunities: A Guide to Regenerative Medicine
April:
Leading-Edge ONCOLOGY
May:
Healthcare Systems & Policies in Asia
June:
Medical Devices and Digital Health Technology
July:
Water Technology
August:
Guest Editorial - Antibody Informatics In Japan
September:
Infectious Diseases
October:
Medical Tourism
November:
Biomedical Imaging Technology
December:
Food Technology
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim/td>
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy